News | August 01, 2025
Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
NewCo’s pipeline includes five investigational medicines
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
His career spans notable tenures at Syngene International Limited, Cipla, Nestlé, and Bharat Petroleum Corporation Limited
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Revenue increased 11.4 per cent to Rs. 8,545 crore
Subscribe To Our Newsletter & Stay Updated
